PE20030830A1 - AMBROXOL FOR THE TREATMENT OF PAINFUL STATES IN THE ORAL CAVITY AND PHARYNGEAL - Google Patents

AMBROXOL FOR THE TREATMENT OF PAINFUL STATES IN THE ORAL CAVITY AND PHARYNGEAL

Info

Publication number
PE20030830A1
PE20030830A1 PE2003000187A PE2003000187A PE20030830A1 PE 20030830 A1 PE20030830 A1 PE 20030830A1 PE 2003000187 A PE2003000187 A PE 2003000187A PE 2003000187 A PE2003000187 A PE 2003000187A PE 20030830 A1 PE20030830 A1 PE 20030830A1
Authority
PE
Peru
Prior art keywords
ambroxol
pharyngeal
treatment
oral cavity
refers
Prior art date
Application number
PE2003000187A
Other languages
Spanish (es)
Inventor
Anke Esperester
Uwe Pschorn
Jean-Michel Vix
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27740434&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20030830(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of PE20030830A1 publication Critical patent/PE20030830A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A LA UTILIZACION DE AMBROXOL O UNA DE SUS SALES FARMACOLOGICAMENTE COMPATIBLES PARA LA PREPARACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ESTADOS DOLOROSOS EN LA CAVIDAD BUCAL Y FARINGEA. SE REFIERE TAMBIEN A UNA COMPOSICION QUE CONTIENE 1)AMBROXOL O UNA DE SUS SALES FARMACOLOGICAMENTE COMPATIBLES; Y, 2)UNO O VARIOS PRINCIPIOS ACTIVOS SELECCIONADOS DE: ANTISEPTICOS, VITAMINAS, CORTICOIDES, ANTIFLOGISTICOS, ANTIBIOTICOS, ANTIMICOTICOS Y ENZIMAS PROTEOLITICAS, COMPOSICION QUE SE UTILIZA PARA LA PREPARACION DE UN MEDICAMENTO CON UN EFECTO ANALGESICO EN UN ESPACIO DE TIEMPO DE POR LO MENOS TRES HORAS DESPUES DE UNA APLICACION. SE REFIERE TAMBIEN A UNA FORMA DE ADMINISTRACION SEMI-SOLIDA EN FORMA DE GEL, CARACTERIZADA PORQUE LA DOSIS INDIVIDUAL ES DE 15 mg A 50 mgREFERS TO THE USE OF AMBROXOL OR ONE OF ITS PHARMACOLOGICALLY COMPATIBLE SALTS FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF PAINFUL CONDITIONS IN THE ORAL CAVITY AND PHARYNGEAL. IT ALSO REFERS TO A COMPOSITION CONTAINING 1) AMBROXOL OR ONE OF ITS PHARMACOLOGICALLY COMPATIBLE SALTS; AND, 2) ONE OR SEVERAL ACTIVE PRINCIPLES SELECTED FROM: ANTISEPTICS, VITAMINS, CORTICOIDES, ANTIPHLOGISTICS, ANTIBIOTICS, ANTIMICOTICS AND PROTEOLITIC ENZYMES, A COMPOSITION THAT IS USED FOR THE PREPARATION OF AN EFFECTS OF A TIME IN SPACE OF A MEDICATION IN A SPACE OF TIME THREE HOURS AFTER AN APPLICATION. IT ALSO REFERS TO A SEMI-SOLID GEL FORM OF ADMINISTRATION, CHARACTERIZED BECAUSE THE INDIVIDUAL DOSE IS FROM 15 mg TO 50 mg

PE2003000187A 2002-02-27 2003-02-26 AMBROXOL FOR THE TREATMENT OF PAINFUL STATES IN THE ORAL CAVITY AND PHARYNGEAL PE20030830A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10208313A DE10208313A1 (en) 2002-02-27 2002-02-27 Ambroxol for the treatment of painful conditions in the mouth and throat

Publications (1)

Publication Number Publication Date
PE20030830A1 true PE20030830A1 (en) 2003-10-31

Family

ID=27740434

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000187A PE20030830A1 (en) 2002-02-27 2003-02-26 AMBROXOL FOR THE TREATMENT OF PAINFUL STATES IN THE ORAL CAVITY AND PHARYNGEAL

Country Status (21)

Country Link
EP (1) EP1480626A1 (en)
JP (1) JP2005518435A (en)
KR (1) KR20040084944A (en)
CN (1) CN1638749A (en)
AR (1) AR038698A1 (en)
AU (1) AU2003210345B2 (en)
BR (1) BR0308038A (en)
CA (1) CA2477105A1 (en)
DE (1) DE10208313A1 (en)
EC (1) ECSP045242A (en)
IS (1) IS7417A (en)
MX (1) MXPA04008220A (en)
MY (1) MY144781A (en)
PE (1) PE20030830A1 (en)
PL (1) PL371584A1 (en)
RU (1) RU2311176C2 (en)
TW (1) TW200306804A (en)
UA (1) UA86741C2 (en)
UY (1) UY27679A1 (en)
WO (1) WO2003072094A1 (en)
ZA (1) ZA200405635B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10332486A1 (en) * 2003-07-16 2005-02-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol for the treatment of acute pain
JP2005120063A (en) * 2003-10-14 2005-05-12 Boehringer Ingelheim Pharma Gmbh & Co Kg Ambroxol for treating inflammation at pharynx
ITMI20032462A1 (en) * 2003-12-16 2005-06-17 Advance Holdings Ltd METHOD TO PREPARE A CARAMEL CONTAINING AMBROXOLO AND THE CANDY SO OBTAINED
DE102004021992A1 (en) * 2004-05-03 2005-11-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Topical preparation containing ambroxol
JP2007084471A (en) * 2005-09-21 2007-04-05 Sunstar Inc Composition for oral cavity and method of selecting product for oral cavity
WO2007110871A2 (en) * 2006-03-29 2007-10-04 Naveh Pharma (1996) Ltd. Methods and composition for treating sore throat
JP5765934B2 (en) * 2009-12-28 2015-08-19 サンスター株式会社 Oral composition
JP6171683B2 (en) * 2012-08-03 2017-08-02 大正製薬株式会社 Solid preparation
CN105769908B (en) * 2016-05-06 2019-03-01 湖北凤凰白云山药业有限公司 A kind of drug of preventing phlegm from forming and stopping coughing and preparation method thereof
KR102116303B1 (en) 2016-11-14 2020-05-29 밍우 왕 Formulations and related methods for treating ocular surface diseases
CN106727621A (en) * 2016-11-22 2017-05-31 郑州仁宏医药科技有限公司 A kind of Western medicine powder for treating toothache
JP6844394B2 (en) * 2017-04-14 2021-03-17 大正製薬株式会社 Solid composition
EP3415143A1 (en) 2017-06-16 2018-12-19 Kai-Uwe Kern Bromhexine for the treatment of pain

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3432411A1 (en) * 1983-09-17 1985-04-11 Dr. Karl Thomae Gmbh, 7950 Biberach ANTIADHAESIVE PROHYLACTICA AND MEDICINAL PRODUCTS CONTAINING A SECRETOLYTICALLY EFFECTIVE BENZYLAMINE DERIVATIVE
DE3445226A1 (en) * 1983-12-14 1985-08-01 Reifenrath, Rainer Richard Otto, Dr.med., 7920 Heidenheim Pharmaceutical product for the treatment and prophylaxis of infections and of coughs and obstructive airway disorders
US5122540A (en) * 1986-02-28 1992-06-16 W. Keith R. Watson Method and composition for treating warts and throat soreness with DMSO and citric acid
DE4415553A1 (en) * 1994-05-03 1995-11-09 Behringwerke Ag Use of deoxyspergualin to prepare medicament
EP0896815A4 (en) * 1996-05-02 2000-02-09 Taisho Pharmaceutical Co Ltd Suspension of sparingly water-soluble acidic drug
DE19933148A1 (en) * 1999-07-20 2001-01-25 Boehringer Ingelheim Int Lozenge containing ambroxol
JP2001151677A (en) * 1999-11-26 2001-06-05 Taisho Pharmaceut Co Ltd Composition for pharyngeal use
DE20102817U1 (en) * 2000-02-23 2001-06-07 Bolder Arzneimittel Gmbh Lozenges and chewing pills with cyclodextrin
US6391886B1 (en) * 2000-12-04 2002-05-21 The Procter & Gamble Company Oral compositions having improved consumer aesthetics

Also Published As

Publication number Publication date
DE10208313A1 (en) 2003-09-11
CN1638749A (en) 2005-07-13
WO2003072094A1 (en) 2003-09-04
BR0308038A (en) 2004-12-28
MXPA04008220A (en) 2004-11-26
RU2004129284A (en) 2005-06-10
UY27679A1 (en) 2003-09-30
AR038698A1 (en) 2005-01-26
JP2005518435A (en) 2005-06-23
ECSP045242A (en) 2004-09-28
IS7417A (en) 2004-08-19
KR20040084944A (en) 2004-10-06
TW200306804A (en) 2003-12-01
AU2003210345B2 (en) 2009-01-29
EP1480626A1 (en) 2004-12-01
AU2003210345A1 (en) 2003-09-09
ZA200405635B (en) 2005-05-31
MY144781A (en) 2011-11-15
CA2477105A1 (en) 2003-09-04
RU2311176C2 (en) 2007-11-27
UA86741C2 (en) 2009-05-25
PL371584A1 (en) 2005-06-27

Similar Documents

Publication Publication Date Title
AR111572A2 (en) PHARMACEUTICAL FORMS CONTAINING VARDENAFILO
AR039744A1 (en) METHODS AND DOSAGE FORMS TO INCREASE THE SOLUBILITY OF PHARMACOS COMPOSITIONS FOR CONTROLLED ADMINISTRATION
AR045972A1 (en) FORMULATIONS OF RELEASE OF SUSTAINED LIBERATION WITH EFFECTIVENESS OF 24 HOURS
ES2180251T3 (en) COMPRESSED COVERED WITH POLYMER, CONTAINING AMOXYCLINE AND CLAVULANATE.
PE20030830A1 (en) AMBROXOL FOR THE TREATMENT OF PAINFUL STATES IN THE ORAL CAVITY AND PHARYNGEAL
NO20043723L (en) Pharmaceutical dosage form for delivery through mucosa
CO5170471A1 (en) MODIFIED RELEASE TABLETS INCLUDING AMOXYLIN AND POTASSIUM CLAVULANATE
AR037255A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING OXIBUTININE
UY25544A1 (en) NEFAZODONE DOSAGE FORM
AR038527A1 (en) DOSAGE FORM CONTAINING A PDE 4 INHIBITOR AS ACTIVE INGREDIENT
AR109644A2 (en) PRADOFLOXACINE AND PHARMACEUTICAL COMPOSITION FOR THE SYSTEMIC TREATMENT OF BACTERIAL DISEASES IN THE ORAL CAVITY
NO20043871L (en) Controlled release drug formulations containing a carrier peptide
UY27296A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING MOSAPRIDE AND PANCREATIN
ECSP034826A (en) METHOD FOR MANUFACTURING A PHARMACEUTICAL COMPOSITION OF LOW DOSE
ATE298324T1 (en) DEUTERATED 3-PIPERIDINOPROPIOPHENONE AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
AR046036A1 (en) RISEDRONATE COMPOSITIONS AND METHODS FOR USE
AP2003002763A0 (en) Controlled release formulations for oral administration
BR0013719A (en) Controlled-release oral dosage, suitable for oral administration
AR035946A1 (en) PHARMACEUTICAL COMPOSITIONS TO USE IN THE TREATMENT OF DISORDERS IN WOMEN PERIMENOPAUSIC, MENOPAUSIC OR POSMENOPAUSIC, AND USES OF SUCH COMPOSITIONS FOR THE PREPARATION OF MEDICINES
BR0308305A (en) Dosage controlled release formulas
AR046410A1 (en) PHARMACEUTICAL COMPOSITIONS FOR MODIFIED LIBERATION OF MODAFINILO
AR022621A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING DEOXIPEGANINE FOR THE TREATMENT OF NICOTINE DEPENDENCE
AR043370A1 (en) PHARMACEUTICAL COMPOSITIONS OF ORAL ADMINISTRATION AND METHODS TO AVOID FOOD-DRUG INTERACTION
BRPI0413374A (en) weak base release compositions for an extended period of time
AR039162A1 (en) VENLAFAXINA FORMULATIONS OF EXTENDED LIBERATION

Legal Events

Date Code Title Description
FC Refusal